Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
Cagrilintide represents a novel approach to obesity management
Rhonda Pacheco to succeed Julie Kim, who was appointed to be Takeda’s next CEO
Maria Soler Nunez appointed as Chief Quality Officer
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
The medicine was well tolerated, with no unexpected safety issue
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
Subscribe To Our Newsletter & Stay Updated
